In 1999, I completed my MBA degree and in January 2000 started working for Bayer as a pharmaceutical sales representative. My first drug to sell was a statin, a cholesterol drug called Lipobay/Baycol. Despite my successes with selling this drug and having the biggest growth in Australia, barely 18 months later Lipobay(cerivastatin) was withdrawn from the market due to rhabdomyalisis (muscle wasting) and deaths. Besides Lipobay, I also sold Ciproxin, Adalat Oros, Avelox, Synvisc & Mycospore.
Lipobay, my first drug to sell to 
General Practitioners.
I was hired by Sanofi and responsible for managing the sales of anti-platelet drug called Plavix. I also sold Panamax and Panadeine Forte and worked for Sanofi both in Perth and Brisbane. After achieving 144% growth of Plavix I was selected to attend Representative Excellence Program offered to the top sales achievers in the company.
I wroked for Eli Lilly for four years. I started working in the neuroscience division, selling Zyprexa and Lovan. It was my great passion to understand the workings of the mind. When our Oxley team was dismanteled, I was re-assigned to work in the diabetes and Womens health division, selling Actos for diabetes and Evista for Osteoporosis. I also sold Cialis, a drug for erectile dysfunction. I pursued my passion for working in the hospitals, and became a Critical Sales Associate working in the area of Interventional cardiology with ReoPro and Intensive Care selling Xigris, which has now been withdrawn from the market following the PROWESS-SHOCK trial, failing to show that Xigris had a survival benefit for patients with severe sepsis and septic shock.
With my knowledge of interventional cardiology, my journey took me to explore this world even deeper. I was offered a position of territory manager responsible for selling Interventional cardiology products, mainly cardiac stents to cardiologists.
At the beginning of my career with Boehringer Ingelheim I was responsible for the sales of Micardis, Spiriva and Asasantin to Queensland Specialists. In 2008 an opportunity came to work in collaboration with Eli Lilly to launch a new antidepressant called Cymbalta. I was successful at securing a specialist role in Psychiatry and sold Cymbalta for 2 years for depression and neuropathic pain. My sucess lead to me being promoted to a senior hospital representative role. I was also trained on Sifrol a drug for Parkinsons disease and Flibancerin a 5HT1A receptor agonist and 5-HT2A receptor antagonist, aimed at the treatment of HSDD, a so called Hyposexual Desire Disorder in women according to DSM IV. As the Phase III studies failed to meet their endpoint, the FDA did not approve this "female viagra" to enter the market. What is interesting to note that flibancerin is actually an antidepressant with an adverse reaction of increased sexual desire, a similar story to viagra unfolds here.